However, this study is the first to observe changes in NFL and Aβ1–42 in all stages of the AD spectrum and suggests a plasma-based biomarker that simultaneously reflects Aβ1–42 pathology and neurodegeneration in the brain. Here, NEFL is linked to Alzheimer disease.